Drugs for Treating Mental Disorders: Technologies and Global Markets

Published by: BCC Research

Published: Jan. 1, 2011 - 178 Pages

Table of Contents

CHAPTER ONE: INTRODUCTION

STUDY GOALS AND OBJECTIVES

REASONS FOR DOING THIS STUDY

SCOPE OF REPORT

METHODOLOGY AND INFORMATION SOURCES

INTENDED AUDIENCE

ANALYST CREDENTIALS

RELATED REPORTS

BCC ONLINE SERVICES

DISCLAIMER

CHAPTER TWO: SUMMARY

SUMMARY

SUMMARY TABLE GLOBAL MENTAL HEALTH PHARMACEUTICAL INDUSTRY BY DRUG CATEGORY, THROUGH 2015 ($ BILLIONS)

SUMMARY FIGURE GLOBAL MENTAL HEALTH PHARMACEUTICAL INDUSTRY BY DRUG CATEGORY, 2009-2015 ($ BILLIONS)

CHAPTER THREE: INTRODUCTION

HISTORICAL OVERVIEW

SCIENTIFIC BREAKTHROUGHS IN MENTAL HEALTH RESEARCH

DRIVERS AND CHALLENGES OF THE MENTAL HEALTH PHARMACEUTICAL MARKET

MENTAL HEALTH ORGANIZATIONS

CITIZENS COMMISSION ON HUMAN RIGHTS (CCHR)

NATIONAL ALLIANCE OF MENTAL ILLNESS (NAMI)

MENTAL HEALTH AMERICA (MHA)

NATIONAL INSTITUTE OF MENTAL HEALTH (NIMH)

GENERAL OVERVIEW OF THE MENTAL HEALTH PHARMACEUTICAL MARKET

TABLE 1 GLOBAL MENTAL HEALTH PHARMACEUTICAL MARKET SHARES BY DRUG CATEGORY, 2010 (%)

FIGURE 1 GLOBAL MENTAL HEALTH PHARMACEUTICAL MARKET SHARES BY DRUG CATEGORY, 2010 (%)

DIAGNOSTICS FOR MENTAL ILLNESSES

OVERVIEW

TABLE 2 U.S. LIFETIME PREVALENCE OF MENTAL HEALTH DISORDERS BY TYPE OF ILLNESS, 2009 (%)

GENETIC FACTORS OF MENTAL HEALTH DISORDERS AND BIOMARKER DEVELOPMENT

TABLE 3 GENETIC FACTORS ASSOCIATED WITH MENTAL HEALTH DISORDERS AND CURRENT DIAGNOSTIC TESTS

Bipolar Disorder

TABLE 4 RISK OF DEVELOPING BIPOLAR DISORDER BASED ON FAMILIAL RELATIONSHIP (%)

ANK3/CACNA1C Gene Candidates

GRK3

New Diagnostic Tools for Bipolar Disorder Based on Genetic Findings

Schizophrenia

TABLE 5 U.S. STATISTICAL RISK OF DEVELOPING SCHIZOPHRENIA BASED ON FAMILIAL RELATIONSHIP (%)

Chromosomal Deletions

CMYA 5

New Diagnostics for Schizophrenia

Depression

New Diagnostics for Depression

BIOMARKER MARKET FOR CNS DISORDERS

TABLE 6 GLOBAL MARKET FORECAST FOR BIOMARKERS FOR CNS DISORDERS AND DIAGNOSTICS TESTS, THROUGH 2015 ($ MILLIONS)

Recent Examples of Biomarker Research Development for Mental Disorders

Examples of Industry-Academia Collaborations as Drivers of Biomarker Development

PSYCHOTHERAPY FOR THE TREATMENT OF MENTAL DISORDERS

TABLE 7 U.S. PSYCHOTHERAPY TREATMENT STATISTICS, 2009

CHAPTER FOUR: DEPRESSION AND THE ANTIDEPRESSANTS DRUG MARKET

DEPRESSIVE DISORDER

DIAGNOSIS OF DEPRESSION

CURRENT DEPRESSION STATISTICS

TABLE 8 U.S. DEPRESSIVE DISORDER STATISTICS, 2010

TREATMENT OPTIONS FOR DEPRESSION

TABLE 9 CURRENT TREATMENT OPTIONS FOR DEPRESSION

ANTIDEPRESSANT DRUGS AS A MEDICAL TREATMENT FOR DEPRESSION

TABLE 10 MAJOR ANTIDEPRESSANT DRUG CATEGORIES

Major Types of Antidepressants

Selective Serotonin Reuptake Inhibitors (SSRIs)

Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)

Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs/Non Tricyclic Antidepressant)

Tricyclic/Tetracyclic Antidepressants (TCAs)

Monoamine Oxidase Inhibitors (MAOIs)

TABLE 11 RATING OF COMMONLY USED ANTIDEPRESSANTS ACCORDING TO EFFICACY AND ACCEPTABILITY

TABLE 12 GLOBAL NET SALES FOR LEXAPRO, PRESTIQ, AND CYMBALTA, THROUGH 2015 ($ BILLIONS)

TABLE 13 AVERAGE ANNUAL ANTIDEPRESSANT PRESCRIPTIONS IN THE U.S., 2009 (MILLIONS)

NEW ANTIDEPRESSANT DRUG DEVELOPMENT

TABLE 14 CURRENT DRUG PIPELINES FOR ANTIDEPRESSANTS, 2010

ANTIDEPRESSANT MARKET PARTICIPANTS ANALYSIS AND FORECAST

TABLE 15 GLOBAL ANTIDEPRESSANT MARKET SHARES BY COMPANY, 2010 AND 2015 (%)

FIGURE 2 GLOBAL ANTIDEPRESSANT MARKET SHARES BY COMPANY, 2010 AND 2015 (%)

NEW AREAS OF ANTIDEPRESSANT RESEARCH

KETAMINE

SCOPOLAMINE

CHAPTER FIVE: ANTIPSYCHOTICS MEDICATION MARKET

OVERVIEW

TABLE 16 GLOBAL MARKET ANALYSIS OF LEADING ANTIPSYCHOTIC MEDICATIONS, 2008 AND 2009 ($ BILLIONS)

NEW ANTIPSYCHOTIC DRUGS

FANAPT

SAPHRIS

INVEGA SUSTENNA

TABLE 17 GLOBAL MARKET SHARES OF LEADING ANTIPSYCHOTIC MEDICATIONS BY COMPANY, 2010 AND 2015 (%)

FIGURE 3 GLOBAL MARKET SHARES OF LEADING ANTIPSYCHOTIC MEDICATIONS BY COMPANY, 2010 AND 2015 (%)

CHAPTER SIX: ANXIETY DISORDERS AND THE DRUG MARKET FOR ANXIOLYTICS

OVERVIEW

TABLE 18 PREVALENCE OF ANXIETY DISORDERS IN THE U.S., 2010 (%)

TABLE 19 MEDICATION TREATMENTS FOR ANXIETY DISORDERS

TYPES OF ANTIANXIETY MEDICATIONS

ANTIDEPRESSANTS

BENZODIAZEPINES

BETA-BLOCKERS

BUSPAR (BUSIPRONE)

TABLE 20 BENZODIAZEPINES USAGE STATISTICS, 2010 (%)

XANAX

TABLE 21 AVERAGE ANNUAL U.S. SALES OF XANAX AND BUSPAR, 2010 ($ MILLIONS)

NON-BENZODIAZEPINE DRUG CANDIDATES AS ANXIOLYTICS

Adipiplon or NG2-73

CGS-9896

Stresam (Etifoxine)

Pagoclone

ADDITIONAL TREATMENT OPTIONS FOR ANXIETY DISORDERS

CURRENT DRUG PIPELINES FOR ANTIANXIETY DRUGS

TABLE 22 CURRENT DRUG PIPELINES FOR ANXIETY TREATMENTS, 2010

NEW PRECLINICAL INDICATIONS IN DRUG DEVELOPMENT FOR ANXIETY DISORDERS

XBD-173/AC-5216

BNC210

CXB722

CHAPTER SEVEN: SCHIZOPHRENIA

OVERVIEW

TABLE 23 U.S. PREVALENCE OF SCHIZOPHRENIA AND HEALTHCARE COSTS, 2009

TABLE 24 STATISTICS FOR NIH RESEARCH FUNDING IN VARIOUS AREAS OF SCIENCE IN THE U.S., 2011 ($)

DIAGNOSIS OF SCHIZOPHRENIA

TREATMENT OF SCHIZOPHRENIA

TABLE 25 CURRENT TREATMENTS FOR SCHIZOPHRENIA AND THEIR EFFICACY

SEROQUEL AND ABILIFY AS REPRESENTATIVE OF THE DRUG MARKET FOR SCHIZOPHRENIA

SEROQUEL

ABILIFY

TABLE 26 GLOBAL SALES OF SEROQUEL AND ABILIFY, THROUGH 2015 ($ BILLIONS)

NEW DRUGS ON THE MARKET FOR THE TREATMENT OF SCHIZOPHRENIA

FANAPT (ILOPERIDONE)

SAPHRIS (ASENAPINE)

NEW DRUG CANDIDATES IN DEVELOPMENT

TABLE 27 CURRENT DRUG PIPELINES FOR SCHIZOPHRENIA TREATMENTS, 2010

EXAMPLES OF NEW COMPOUNDS IN DEVELOPMENT

LY2140023

Latuda (Lurasidone) -- Recently Approved for Schizophrenia

Preclinical Trials on Compounds that Target the Glutamate System

EXAMPLES OF COLLABORATIONS IN SCHIZOPHRENIA RESEARCH

NEWMEDS (New Medications in Depression and Schizophrenia)

Cypress Bioscience/BioLineRx

Janssen Pharmaceutical/Vanderbilt University program

Drugs Currently on the Market Testing for the New Indication of Schizophrenia

MARKET ANALYSIS OF THE SCHIZOPHRENIA DRUG MARKET

TABLE 28 GLOBAL COMPANY SHARES OF ONGOING CLINICAL TRIALS FOR SCHIZOPHRENIA DRUG TREATMENTS, 2010 (NUMBER/%)

CHAPTER EIGHT: CHILDHOOD AND ADOLESCENT MENTAL DISORDERS

OVERVIEW

TABLE 29 PREVALENCE OF MENTAL DISORDERS IN CHILDREN AND ADOLESCENTS IN THE U.S., 2010

TYPES OF MENTAL DISORDERS

ADHD (ATTENTION DEFICIT HYPERACTIVITY DISORDER)

ADHD Treatments

TABLE 30 DRUG TREATMENTS FOR ADHD

Market Analysis for ADHD Treatments

TABLE 31 NET SALES OF VYVANSE AND STRATTERA IN THE U.S., THROUGH 2015 ($ MILLIONS)

ADHD Drug Market for Adults

TABLE 32 U.S. STATISTICS FOR ADHD IN ADULTS, 2010

New Drug Developments for ADHD Treatments

TABLE 33 CURRENT DRUG PIPELINES FOR ADHD, 2010

Alternative and New Treatments for ADHD

Neurofeedback/EEG (Electroencephalogram)/Biofeedback

Green Time Activities

Behavior Therapy and Homeopathic Remedies

AUTISM SPECTRUM DISORDER

TABLE 34 U.S. AUTISM STATISTICS, 2009

Treatment of Autism

TABLE 35 CURRENT MEDICATIONS FOR AUTISM

New Treatments for Autism

TABLE 36 CURRENT DRUG PIPELINES FOR AUTISM TREATMENTS, 2010

KM-391

STK-209 (Arbaclofen)

CM-AT

CHAPTER NINE: BIPOLAR DISORDER

OVERVIEW

TABLE 37 U.S. BIPOLAR DISORDER STATISTICS, 2010

CAUSES OF BIPOLAR DISORDER AND DIAGNOSIS

BIPOLAR DISORDER TREATMENTS

TABLE 38 CURRENT DRUG TREATMENTS FOR BIPOLAR DISORDER

ANXYOLITICS

ANTYPSYCHOTICS

MOOD STABILIZERS

OFF-LABEL DRUG TREATMENTS FOR BIPOLAR DISORDER

TABLE 39 OFF-LABEL MEDICATIONS FOR BIPOLAR DISORDER

Anticonvulsants

ABS-103

Topamax

Mood Stabilizers

Neorontin

Tegretol

Antidepressant (Lamictal)

DRUGS UNDER INVESTIGATION TO TREAT BIPOLAR DISORDER

Zyprexa

Seroquel

NEW DRUG DEVELOPMENTS TO TREAT BIPOLAR DISORDER

SAPHRIS

SUBSTANCE P-BLOCKERS

TABLE 40 CURRENT DRUG PIPELINES FOR BIPOLAR DISORDER TREATMENTS, 2010

MARKET ANALYSIS OF BIPOLAR DISORDER DRUGS

TABLE 41 GLOBAL MARKET FOR DRUGS TO TREAT BIPOLAR DISORDER, THROUGH 2015 ($ BILLIONS)

CHAPTER TEN: EATING DISORDERS

OVERVIEW

TABLE 42 U.S. EATING DISORDER STATISTICS, 2010

TYPES OF EATING DISORDERS

ANOREXIA NERVOSA

BINGE EATING

BULIMIA NERVOSA

OBESITY

EATING DISORDER TREATMENTS

TABLE 43 CURRENT DRUG TREATMENTS FOR EATING DISORDERS

ECONOMIC COSTS OF TREATING EATING DISORDERS

TABLE 44 AVERAGE COST OF TREATING EATING DISORDERS IN THE U.S., 2010

NEW DRUG DEVELOPMENTS FOR EATING DISORDERS

TABLE 45 CURRENT DRUG PIPELINES FOR EATING DISORDER TREATMENTS, 2010

CHAPTER ELEVEN: COGNITIVE DISORDERS AS MENTAL HEALTH ILLNESSES

OVERVIEW

TABLE 46 GLOBAL DEMENTIA AND DELIRIUM STATISTICS, 2010

DEMENTIA

TYPES OF ILLNESS-RELATED DEMENTIA

Alzheimer’s-Related Dementia

Vascular Dementia

Parkinson’s-Related Dementia

TABLE 47 U.S PREVALENCE OF ALZHEIMER’S AND PARKINSON’S DISEASE AND TREATMENT COSTS, 2010 ($ BILLIONS)

DRUGS FOR TREATING DEMENTIA

TABLE 48 CURRENT TREATMENTS FOR DEMENTIA

Acetylcholinesterase Inhibitors

N-methyl-D Aspartate Blockers

Clioquinol

Eldepryl (Selegeline)

Additional Treatments

ALZHEIMER’S AS THE MOST PROFITABLE MARKET FOR DEMENTIA TREATMENTS

TABLE 49 GLOBAL ALZHEIMER’S DRUG MARKET, THROUGH 2015 ($ BILLIONS)

TABLE 50 GLOBAL NET SALES OF NAMENDA AND ARICEPT, THROUGH 2015 ($ BILLIONS)

TABLE 51 DRUG PIPELINES FOR DEMENTIA BY RELATED CONDITION/INDICATION: ALZHEIMER’S, COGNITIVE DISORDERS, AND SCHIZOPHRENIA, 2010

PARKINSON’S AS A POTENTIAL MARKET FOR DEMENTIA TREATMENTS

TABLE 52 GLOBAL NET SALES OF MITAPEX AND REQUIP, 2007-2009 ($ MILLIONS)

DELIRIUM

AMNESIA

TABLE 53 TYPES AND CAUSES OF AMNESIA

EPILEPSY-RELATED DEFICITS IN COGNITION

TABLE 54 GLOBAL EPILEPSY AND ANTI-SEIZURE TREATMENT MARKET ANALYSIS, 2010 ($ BILLIONS/%)

TABLE 55 GLOBAL ESTIMATED EPILEPSY/ANTI-SEIZURE DRUG MARKET, THROUGH 2015 ($ BILLIONS)

TABLE 56 CURRENT DRUG/DEVICE PIPELINES FOR EPILEPSY TREATMENTS, 2010

MEMORY ENHANCEMENT MEDICATION (NOOTROPICS)

CHAPTER TWELVE: SUBSTANCE AND ALCOHOL ADDICTIONS AS MENTAL HEALTH DISORDERS

OVERVIEW

TABLE 57 U.S. DRUG/ALCOHOL ABUSE TREATMENT STATISTICS, 2010 (MILLIONS)

ECONOMIC COSTS OF ALCOHOL AND DRUG ABUSE

TABLE 58 ECONOMIC COST OF SUBSTANCE ABUSE IN THE U.S., 2010 ($ BILLIONS)

MEDICATIONS AND TREATMENT FOR DRUG/ALCOHOL ABUSE

TABLE 59 CURRENT MEDICATIONS USED IN THE TREATMENT OF SUBSTANCE ABUSE

TYPES OF ADDICTIONS AND THEIR TREATMENT OPTIONS

SUBSTANCE ABUSE MARKET ANALYSIS

TABLE 60 GLOBAL NET SALES OF VIVITROL, THROUGH 2015 ($ MILLIONS)

NEW DRUG DEVELOPMENTS FOR THE TREATMENT OF SUBSTANCE ABUSE

TABLE 61 DRUG PIPELINES FOR SUBSTANCE ABUSE TREATMENTS BY CONDITION, 2010

CHAPTER THIRTEEN: PERSONALITY DISORDERS

OVERVIEW

TABLE 62 U.S. PREVALENCE OF PERSONALITY DISORDERS WITH DESCRIPTIONS, 2007

TREATMENTS FOR PERSONALITY DISORDERS

NEW DRUG DEVELOPMENTS FOR PERSONALITY DISORDERS

TABLE 63 CURRENT DRUG PIPELINES FOR THE TREATMENT OF PERSONALITY DISORDERS, 2010

CHAPTER FOURTEEN: SLEEP DISORDERS AS MENTAL HEALTH CONDITIONS

OVERVIEW

TABLE 64 U.S. PREVALENCE OF SLEEP DISORDERS AND HEALTHCARE COSTS, 2010

TREATMENTS FOR SLEEP DISORDERS

TABLE 65 CURRENT MEDICATIONS FOR SLEEP DISORDERS

TABLE 66 GLOBAL SLEEP DISORDER DRUG SALES BY MARKET LEADERS, 2009 ($ MILLIONS)

NEW DRUG PIPELINES FOR THE TREATMENT OF SLEEP DISORDERS

TABLE 67 DRUG PIPELINES FOR SLEEP DISORDER TREATMENTS, 2010

CHAPTER FIFTEEN: ADDITIONAL MARKETS FOR DRUGS TO TREAT MENTAL DISORDERS

FRAGILE X SYNDROME

PREMENSTRUAL SYNDROME

TABLE 68 DRUG PIPELINES FOR VARIOUS MENTAL CONDITIONS, 2010

CHAPTER SIXTEEN: MENTAL HEALTH PHARMACEUTICAL MARKETS BY GEOGRAPHIC REGION

ANTIDEPRESSSANTS MARKETED IN JAPAN

TABLE 69 ANTIDEPRESSANT DRUGS MARKETED IN JAPAN, 1999-2011

TABLE 70 GLOBAL ANTIDEPRESSANT MARKET SHARE FORECAST BY GEOGRAPHIC REGION, 2010 AND 2015 (%)

FIGURE 4 GLOBAL ANTIDEPRESSANT MARKET SHARE FORECAST BY GEOGRAPHIC REGION, 2010 AND 2015

MENTAL HEALTH DRUGS MARKETED IN OTHER GEOGRAPHIC REGIONS

TABLE 71 GLOBAL MARKET SHARES OF VARIOUS TYPES OF MENTAL HEALTH DRUGS BY GEOGRAPHIC REGION, 2010 (%)

FIGURE 5 GLOBAL MARKET SHARES OF VARIOUS TYPES OF MENTAL HEALTH DRUGS BY GEOGRAPHIC REGION, 2010 (%)

CHAPTER SEVENTEEN: EXAMPLES OF ECONOMIC COSTS IN TREATING MENTAL DISORDERS

TABLE 72 U.S. AVERAGE ANNUAL HEALTHCARE COSTS PER PATIENT WITH BIPOLAR DISORDER, 2010 ($/%)

TABLE 73 U.S. COSTS OF TREATING ADHD, 2010

CHAPTER EIGHTEEN: LEGAL ISSUES AND LAWSUITS IN THE PHARMACEUTICAL INDUSTRY FOR MENTAL DISORDERS

TABLE 74 RECENT EXAMPLES OF MENTAL HEALTH DRUG COMPANY LAWSUITS, 2007-2010 ($ MILLIONS)

DRUGS INVOLVED IN LITIGATION

ZYPREXA

SEROQUEL

ABILIFY

RISPERDAL

CHAPTER NINETEEN: MARKET SUMMARY

OVERVIEW

TABLE 75 GLOBAL MENTAL HEALTH PHARMACEUTICALS BY DRUG CATEGORY, THROUGH 2015 ($ BILLIONS)

FIGURE 6 GLOBAL MENTAL HEALTH PHARMACEUTICALS BY DRUG CATEGORY, 2009-2015 ($ BILLIONS)

NEW PIPELINES AS A FORECAST OF MARKET DEVELOPMENT

TABLE 76 ANALYSIS OF CURRENT DRUG PIPELINES IN THE MENTAL HEALTH PHARMACEUTICAL INDUSTRY (NUMBER/%)

MAJOR MARKET PARTICIPANTS IN THE MENTAL HEALTH PHARMACEUTICAL INDUSTRY

PFIZER

ELI LILLY

GLAXOSMITHKLINE

ASTRAZENECA

BRISTOL-MYERS SQUIBB

JOHNSON & JOHNSON

SELECTED COMPANY PROFILES

ASTRAZENECA

BRISTOL-MYERS SQUIBB

ELI LILLY AND CO.

GLAXOSMITHKLINE, PLC

JOHNSON & JOHNSON

PFIZER, INC.

LIST OF COMPANIES DISCUSSED IN REPORT

APPENDIX ONE: ACRONYMS

APPENDIX TWO: LIST OF ADDITIONAL SOURCES

LIST OF ADDITIONAL SOURCES

LIST OF TABLES

SUMMARY TABLE GLOBAL MENTAL HEALTH PHARMACEUTICAL INDUSTRY BY DRUG CATEGORY, THROUGH 2015 ($ BILLIONS)

TABLE 1 GLOBAL MENTAL HEALTH PHARMACEUTICAL MARKET SHARES BY DRUG CATEGORY, 2010 (%)

TABLE 2 U.S. LIFETIME PREVALENCE OF MENTAL HEALTH DISORDERS BY TYPE OF ILLNESS, 2009 (%)

TABLE 3 GENETIC FACTORS ASSOCIATED WITH MENTAL HEALTH DISORDERS AND CURRENT DIAGNOSTIC TESTS

TABLE 4 RISK OF DEVELOPING BIPOLAR DISORDER BASED ON FAMILIAL RELATIONSHIP (%)

TABLE 5 U.S. STATISTICAL RISK OF DEVELOPING SCHIZOPHRENIA BASED ON FAMILIAL RELATIONSHIP (%)

TABLE 6 GLOBAL MARKET FORECAST FOR BIOMARKERS FOR CNS DISORDERS AND DIAGNOSTICS TESTS, THROUGH 2015 ($ MILLIONS)

TABLE 7 U.S. PSYCHOTHERAPY TREATMENT STATISTICS, 2009

TABLE 8 U.S. DEPRESSIVE DISORDER STATISTICS, 2010

TABLE 9 CURRENT TREATMENT OPTIONS FOR DEPRESSION

TABLE 10 MAJOR ANTIDEPRESSANT DRUG CATEGORIES

TABLE 11 RATING OF COMMONLY USED ANTIDEPRESSANTS ACCORDING TO EFFICACY AND ACCEPTABILITY

TABLE 12 GLOBAL NET SALES FOR LEXAPRO, PRESTIQ, AND CYMBALTA, THROUGH 2015 ($ BILLIONS)

TABLE 13 AVERAGE ANNUAL ANTIDEPRESSANT PRESCRIPTIONS IN THE U.S., 2009 (MILLIONS)

TABLE 14 CURRENT DRUG PIPELINES FOR ANTIDEPRESSANTS, 2010

TABLE 15 GLOBAL ANTIDEPRESSANT MARKET SHARES BY COMPANY, 2010 AND 2015 (%)

TABLE 16 GLOBAL MARKET ANALYSIS OF LEADING ANTIPSYCHOTIC MEDICATIONS, 2008 AND 2009 ($ BILLIONS)

TABLE 17 GLOBAL MARKET SHARES OF LEADING ANTIPSYCHOTIC MEDICATIONS BY COMPANY, 2010 AND 2015 (%)

TABLE 18 PREVALENCE OF ANXIETY DISORDERS IN THE U.S., 2010

(%)

TABLE 19 MEDICATION TREATMENTS FOR ANXIETY DISORDERS

TABLE 20 BENZODIAZEPINES USAGE STATISTICS, 2010

(%)

TABLE 21 AVERAGE ANNUAL U.S. SALES OF XANAX AND BUSPAR, 2010 ($ MILLIONS)

TABLE 22 CURRENT DRUG PIPELINES FOR ANXIETY TREATMENTS, 2010

TABLE 23 U.S. PREVALENCE OF SCHIZOPHRENIA AND HEALTHCARE COSTS, 2009

TABLE 24 STATISTICS FOR NIH RESEARCH FUNDING IN VARIOUS AREAS OF SCIENCE IN THE U.S., 2011 ($)

TABLE 25 CURRENT TREATMENTS FOR SCHIZOPHRENIA AND THEIR EFFICACY

TABLE 26 GLOBAL SALES OF SEROQUEL AND ABILIFY, THROUGH 2015 ($ BILLIONS)

TABLE 27 CURRENT DRUG PIPELINES FOR SCHIZOPHRENIA TREATMENTS, 2010

TABLE 28 GLOBAL COMPANY SHARES OF ONGOING CLINICAL TRIALS FOR SCHIZOPHRENIA DRUG TREATMENTS, 2010 (NUMBER/%)

TABLE 29 PREVALENCE OF MENTAL DISORDERS IN CHILDREN AND ADOLESCENTS IN THE U.S., 2010

TABLE 30 DRUG TREATMENTS FOR ADHD

TABLE 31 NET SALES OF VYVANSE AND STRATTERA IN THE U.S., THROUGH 2015 ($ MILLIONS)

TABLE 32 U.S. STATISTICS FOR ADHD IN ADULTS, 2010

TABLE 33 CURRENT DRUG PIPELINES FOR ADHD, 2010

TABLE 34 U.S. AUTISM STATISTICS, 2009

TABLE 35 CURRENT MEDICATIONS FOR AUTISM

TABLE 36 CURRENT DRUG PIPELINES FOR AUTISM TREATMENTS, 2010

TABLE 37 U.S. BIPOLAR DISORDER STATISTICS, 2010

TABLE 38 CURRENT DRUG TREATMENTS FOR BIPOLAR DISORDER

TABLE 39 OFF-LABEL MEDICATIONS FOR BIPOLAR DISORDER

TABLE 40 CURRENT DRUG PIPELINES FOR BIPOLAR DISORDER TREATMENTS, 2010

TABLE 41 GLOBAL MARKET FOR DRUGS TO TREAT BIPOLAR DISORDER, THROUGH 2015 ($ BILLIONS)

TABLE 42 U.S. EATING DISORDER STATISTICS, 2010

TABLE 43 CURRENT DRUG TREATMENTS FOR EATING DISORDERS

TABLE 44 AVERAGE COST OF TREATING EATING DISORDERS IN THE U.S., 2010

TABLE 45 CURRENT DRUG PIPELINES FOR EATING DISORDER TREATMENTS, 2010

TABLE 46 GLOBAL DEMENTIA AND DELIRIUM STATISTICS, 2010

TABLE 47 U.S PREVALENCE OF ALZHEIMER’S AND PARKINSON’S DISEASE AND TREATMENT COSTS, 2010 ($ BILLIONS)

TABLE 48 CURRENT TREATMENTS FOR DEMENTIA

TABLE 49 GLOBAL ALZHEIMER’S DRUG MARKET, THROUGH 2015 ($ BILLIONS)

TABLE 50 GLOBAL NET SALES OF NAMENDA AND ARICEPT, THROUGH 2015 ($ BILLIONS)

TABLE 51 DRUG PIPELINES FOR DEMENTIA BY RELATED CONDITION/INDICATION: ALZHEIMER’S, COGNITIVE DISORDERS, AND SCHIZOPHRENIA, 2010

TABLE 52 GLOBAL NET SALES OF MITAPEX AND REQUIP, 2007-2009 ($ MILLIONS)

TABLE 53 TYPES AND CAUSES OF AMNESIA

TABLE 54 GLOBAL EPILEPSY AND ANTI-SEIZURE TREATMENT MARKET ANALYSIS, 2010 ($ BILLIONS/%)

TABLE 55 GLOBAL ESTIMATED EPILEPSY/ANTI-SEIZURE DRUG MARKET, THROUGH 2015 ($ BILLIONS)

TABLE 56 CURRENT DRUG/DEVICE PIPELINES FOR EPILEPSY TREATMENTS, 2010

TABLE 57 U.S. DRUG/ALCOHOL ABUSE TREATMENT STATISTICS, 2010 (MILLIONS)

TABLE 58 ECONOMIC COST OF SUBSTANCE ABUSE IN THE U.S., 2010 ($ BILLIONS)

TABLE 59 CURRENT MEDICATIONS USED IN THE TREATMENT OF SUBSTANCE ABUSE

TABLE 60 GLOBAL NET SALES OF VIVITROL, THROUGH 2015 ($ MILLIONS)

TABLE 61 DRUG PIPELINES FOR SUBSTANCE ABUSE TREATMENTS BY CONDITION, 2010

TABLE 62 U.S. PREVALENCE OF PERSONALITY DISORDERS WITH DESCRIPTIONS, 2007

TABLE 63 CURRENT DRUG PIPELINES FOR THE TREATMENT OF PERSONALITY DISORDERS, 2010

TABLE 64 U.S. PREVALENCE OF SLEEP DISORDERS AND HEALTHCARE COSTS, 2010

TABLE 65 CURRENT MEDICATIONS FOR SLEEP DISORDERS

TABLE 66 GLOBAL SLEEP DISORDER DRUG SALES BY MARKET LEADERS, 2009 ($ MILLIONS)

TABLE 67 DRUG PIPELINES FOR SLEEP DISORDER TREATMENTS, 2010

TABLE 68 DRUG PIPELINES FOR VARIOUS MENTAL CONDITIONS, 2010

TABLE 69 ANTIDEPRESSANT DRUGS MARKETED IN JAPAN, 1999-2011

TABLE 70 GLOBAL ANTIDEPRESSANT MARKET SHARE FORECAST BY GEOGRAPHIC REGION, 2010 AND 2015 (%)

TABLE 71 GLOBAL MARKET SHARES OF VARIOUS TYPES OF MENTAL HEALTH DRUGS BY GEOGRAPHIC REGION, 2010 (%)

TABLE 72 U.S. AVERAGE ANNUAL HEALTHCARE COSTS PER PATIENT WITH BIPOLAR DISORDER, 2010 ($/%)

TABLE 73 U.S. COSTS OF TREATING ADHD, 2010

TABLE 74 RECENT EXAMPLES OF MENTAL HEALTH DRUG COMPANY LAWSUITS, 2007-2010 ($ MILLIONS)

TABLE 75 GLOBAL MENTAL HEALTH PHARMACEUTICALS BY DRUG CATEGORY, THROUGH 2015 ($ BILLIONS)

TABLE 76 ANALYSIS OF CURRENT DRUG PIPELINES IN THE MENTAL HEALTH PHARMACEUTICAL INDUSTRY (NUMBER/%)

LIST OF FIGURES

SUMMARY FIGURE GLOBAL MENTAL HEALTH PHARMACEUTICAL INDUSTRY BY DRUG CATEGORY, 2009-2015 ($ BILLIONS)

FIGURE 1 GLOBAL MENTAL HEALTH PHARMACEUTICAL MARKET SHARES BY DRUG CATEGORY, 2010 (%)

FIGURE 2 GLOBAL ANTIDEPRESSANT MARKET SHARES BY COMPANY, 2010 AND 2015 (%)

FIGURE 3 GLOBAL MARKET SHARES OF LEADING ANTIPSYCHOTIC MEDICATIONS BY COMPANY, 2010 AND 2015 (%)

FIGURE 4 GLOBAL ANTIDEPRESSANT MARKET SHARE FORECAST BY GEOGRAPHIC REGION, 2010 AND 2015

FIGURE 5 GLOBAL MARKET SHARES OF VARIOUS TYPES OF MENTAL HEALTH DRUGS BY GEOGRAPHIC REGION, 2010 (%)

FIGURE 6 GLOBAL MENTAL HEALTH PHARMACEUTICALS BY DRUG CATEGORY, 2009-2015 ($ BILLIONS)

Abstract

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.